Abdel-Magid, et al., “Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures1”, J. Org. Chem., 1996, p. 3849-3862, vol. 61. |
Bagshawe, “Anti-Body Directed Enzyme Prodrug Therapy: A Review”, Drug, Dev. Res., 1995, pp. 220-230, vol. 34. |
Bertolini, et al., “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug”, J. Med. Chem. 1997, pp. 2011-2016, vol. 40. |
Bodor, “Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems”, Advances in Drug Res., 1984, pp. 224-231, vol. 13. |
Bowers, et al., “On the Inhibitory Effects of Luteinizing Hormone-Releasing Hormone Analogs”, Endocrinology, 1980, pp. 674-683, vol. 106. (in vitro). |
Bundgaard, Design of Prodrugs, (1985, Elsevier Press; Amsterdam—New York—Oxford). |
Chapman, et al., “Synthesis of NN-Dialkyl-N′-arylalkyl-N′-4-quinazolyl(or 6-methyl-4-pyrimidyl or 4-methyl-2pyrimidyl)ethylenediamines of Potential Pharmacological Interest”, J. Chem. Soc., 1961, pp. 1908-1918. |
Cheng, et al., “Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I50) of an Enzymatic Reaction*”, Biochemical Pharmacol., 1973, pp. 3099-3108, vol. 22. |
Cho, et al., “Discovery of a Novel, Potent, and Orally Active Nonpeptide Antagonist of the Human Luteinizing Hormone-Releasing Hormone (LHRH) Receptor”, J. Med. Chem., 1998, p. 4190-4195, vol. 41(22). |
Corbin, et al., “Inhibition of the Pre-Ovulatory Proestrous Gonadotropin Surge, Ovulation and Pregnancy with a Peptide Analogue of Luteinizing Hormone Releasing Hormone”, Endocr. Res. Commun., 1975, pp. 1-23, vol. 2. |
Dear, et al., “Mass Directed Peak Selection, an Efficient Method of Drug Metabolite Identification Using Directly Coupled Liquid Chromatography—Mass Spectrometry—Nuclear Magnetic Resonance Spectroscopy”, J. Chromatogr. B, 2000, pp. 281-293, vol. 748. |
Goetz, “Research Letters: Decreased Recovery of CD4 Lymphocytes in Older HIV-infected Patients Beginning Highly Active Antiretroviral Therapy”, AIDS, 2001, pp. 1576-1578, vol. 15. |
Harms, et al., “A Rapid and Simple Procedure for Chronic Cannulation of the Rat Jugular Vein”, Applied Physiol., 1974, pp. 391-392, vol. 36. |
Harnden, et al. “Synthesis of Compounds with Potential Central Nervous System Stimulant Activity. II. 5-Spiro-Substituted 2-Amino-2-oxazolines”, J. Med. Chem., 1970, pp. 305-308. |
Jungwirth, et al., “Luteinizing Hormone-Releasing Hormone Antagonist Cetrorelix (SB-75) and Bombesin Antagonist RC-3940-II Inhibit the Growth of Androgen-Independent PC-3 Prosate Cancer in Nude Mice”, Prostate, 1997, pp. 164-172, vol. 32(3). |
Koppan, et al., “Targeted Cytotoxic Analog of Luteinizing Hormone-Releasing Hormone AN-207 Inhibits the Growth of PC-82 Human Prostate Cancer in Nude Mice”, Prostate, 1999, p. 151-158, vol. 38(2). |
Kottler, et al., “The Genes for Gonadotropin-Releasing Hormone and Its Receptor are Expressed in Human Breast with Fibrocystic Disease and Cancer”, Int. J. Cancer, 1997, pp. 595-599, vol. 71(4). |
Larsen, “Design and Application of Prodrugs”, Drug Design and Development, (1991, Krogsgaard-Larsen et al eds., Harwood Academic Publishers). |
Montagnani, et al., “Effects of LHRH Agonists on the Growth of Human Prostatic Tumor Cells: ‘in vitro’ and ‘in vivo’ Studies”, Arch. Ital. Urol. Androl., 1997, pp. 257-263, vol. 69(4). |
Nagy, et al., “Stability of Cytotoxic Luteinizing Hormone-Releasing Hormone Conjugate (AN-152) Containing Doxorubicin 14-O-Hemiglutarate in Mouse and Human Serum in Vitro: Implications for the Design of Preclinical Studies”, Proc Natl Acad Sci USA, 2000, pp. 829-834, vol. 97(2). |
Norwood Abbey press release dated Mar. 5, 2001, “Norwood Abbey Announces Breakthrough In Immunology”. |
Prox, et al., “Rapid Structure Elucidation of Drug Metabolites by Use of Stable Isotopes”, Xenobiol., 1992, pp. 103-112, vol. 3(2). |
Scriabine, “Methode de Preparation des ω-aminopentanols et des Piperidines Substituees a L'azote (8)”, Bull. Soc. Chim. Fr., 1947, p. 454-456, vol. 14. |
Shan, et al., “Prodrug Strategies Based on Intramolecular Cyclization Reactions”, J. Pharm. Sci., 1997, pp. 765-767, vol. 86(7). |
Singh, “Rearrangement of β-lonone to 1,1,6-Trimethyltetralin”, Indian J. Chem. Sect. B, 1984, 23B(1), pp. 87-88. |
Spraul, et al., “Liquid Chromatography Coupled with High-Field Proton NMR for Profiling Human Urine for Endogenous Compounds and Drug Metabolites”, J. Pharmaceutical & Biomedical Analysis, 1992, pp. 601-605, vol. 10(8). |
Srkalovic, et al., “Presence and Characteristics of Receptors for [D-Trp 6 ] Luteinizing Hormone Releasing Hormone and Epidermal Growth Factor in Human Ovarian Cancer”, Int. J. Oncol., 1998, pp. 489-498, vol. 12(3). |
Still, et al., “Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution”, A.J. Org. Chem., 1978, p. 2923, vol. 43. |
Walsh, et al., “Potent Antagonists of Gonadotropin Releasing Hormone Receptors Derived from Quinolone-6-Carboxamides”, Bioorg & Med Chem Ltrs., 2000, pp. 443-447, vol. 10. |